The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide

Peptides

Volumn 24, Issue 9, 2003, Pages 1413-1423

  Ashur Fabian, Osnat ^a   Segal Ruder, Yael ^a   Skutelsky, Ehud ^a   Brenneman, Douglas E ^b   Steingart, Ruth A ^a   Giladi, Eliezer ^a   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Activity dependent neuroprotective protein; Alzheimer's disease; A aggregation; Brain cortical cultures; NAP; Vasoactive intestinal peptide

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; ASPARAGINYLALANYLPROLINE; BIOTIN; CONGO RED; NEUROPROTECTIVE AGENT; PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FLUOROMETRY; HIGH THROUGHPUT SCREENING; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; RAT;

EID: 0347990378     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2003.08.005     Document Type: Article

References (56)

1. Akira M., Ken-Ichiro T., Ichiro Y., Yoshihito H., Yobotada T. Laminin inhibits Aβ42 fibril formation in vitro. Brain Res. 788:1998;187-190.
2. Atwood C.S., Moir R.D., Huang X., Bacarra N.M.E., Scarpa R.C., Romano D.M.et al. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273:1998;12817-12826.
3. Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P. et al. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75:2000;1219-1233.
4. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O.et al. Complete sequence of a novel protein containing a femtomolar-activity- dependent neuroprotective peptide. J. Neurochem. 72:1999;1283-1293.
5. Beni-Adani L., Gozes I., Cohen Y., Assaf Y., Steingart R.A., Brenneman D.E.et al. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J. Pharmacol. Exp. Ther. 296:2001;57-63.
6. Brera B., Serrano A., de Ceballos M.L. Beta-amyloid peptides are cytotoxic to astrocytes in cultures a role for oxidative stress. Neurobiol. Dis. 7:2000;395-405.
7. Bronfman F.C., Garrido J., Alvarez A., Morgan C., Inestrosa N. Laminin inhibits amyloid-β-peptide fibrilation. Neurosci. Lett. 218:1996;201-203.
8. Carter D.B., Dunn E., McKinley D.D., Stratman N.C., Boyle T.P., Kuiper S.L.et al. Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann. Neurol. 50:2001;468-475.
9. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M.et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:1999;271-276.
10. Clement A., Walsh D.M., Williams C.H., Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid β/A4 peptide. Neurosci. Lett. 161:1993;17-20.
11. Esler W.P., Stimson E.R., Ghilardi J.R., Felix A.M., Lu Y.A., Vinters H.V.et al. Aβ deposition inhibitor screen using synthetic amyloid. Nat. Biothech. 15:1997;258-263.
12. Forsythe I.D., Westbrook G.L. Slow excitatory postsynaptic currents mediated by N-methyl-D-aspartate receptors on cultured mouse central neurons. J. Physiol. 396:1988;515-533.
13. Ghanta J., Shen C.L., Kiessling L.L., Murphy R.M. A strategy for designing inhibitors of β-amyloid toxicity. J. Biol. Chem. 271:1996;29525-29528.
14. Gottlieb P., Beretz A., Fridkin M. Tuftsin analogs for probing its specific receptor site on phagocytic cells. Eur. J. Biochem. 125:1982;631-638.
15. Gozes I., Bardea A., Reshef A., Zamostiatno R., Zhukovsky S., Rubinraut S.et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. U.S.A. 93:1996;427-432.
16. Gozes I., Bachar M., Bardea A., Davidson A., Rubinraut S., Fridkin M.et al. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J. Neurobiol. 33:1997;329-342.
17. Gozes I., Bassan M., Zamostiano R., Pinhasov A., Davidson A., Perl O.et al. A novel signaling molecule for neuropeptide action: dependent neuroprotective protein. Ann. N.Y. Acad. Sci. 897:1999;125-135.
18. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 293:2000;1091-1098.
19. Gozes I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci. 24:2001;700-705.
20. Hetenyi C., Kortvelyesi T., Penke B. Mapping of possible binding sequences of two beta-sheet breaker peptides on beta amyloid peptide of Alzheimer's disease. Bioorg. Med. Chem. 10:2002;1587-1593.
21. Hughes S.R., Khorkova O., Goyal S., Knaeblein J., Heroux J., Riedel N.G.et al. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril-formation. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3275-3280.
22. Jarrett J.T., Lansbury P.T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scarpie? Cell. 73:1993;1055-1058.
23. Kerkoski P., Soninen H., Pirttila T. Beta amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell functionality. Neurochem. Int. 38:2001;127-134.
24. Kudva Y.C., Hiddinga H.J., Butler P.C., Mueske C.S., Eberhardt N.L. Small heat shock proteins inhibit in vitro Aβ 1-42 amyloidogenesis. FEBS Lett. 416:1997;117-121.
25. Lambri M., Djurovic V., Kibble M., Cairns N., Al-Sarraj S. Specificity and sensitivity of betaAPP in head injury. Clin. Neuropathol. 20:2001;263-271.
26. Leker R.R., Teichner A., Grigoriadis N., Ovadia H., Brenneman D.E., Fridkin M.et al. NAP, a femtomolar acting peptide protects the brain against ischemic injury by reducing apoptotic death. Stroke. 33:2002;1085-1092.
27. Levine H. Stopped-flow kinetics reveal multiple phases of thioflavine T binding to Alzheimer's β(1-40) amyloid fibrils. Arch. Biochem. Biophys. 342:1997;306-316.
28. Martin D., Salinas M., Lopez-Valdaliso R., Serrano E., Recuero M., Cuadrado A. Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. J. Neurochem. 78:2001;1000-1008.
29. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82:1985;4245-4249.
30. McCarthy K.D., De Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 85:1980;890-902.
31. Monji A., Ken-Ichiro T., Yoshida I., Hayashi Y., Tashiro N. Laminin inhibits Aβ42 fibril formation in vitro. Brain Res. 788:1998;187-190.
32. Moreno-Flores M.T., Salinero O., Wandosell F. Beta amyloid peptide (25-35) induced APP expression in cultured astrocytes. J. Neurosci. Res. 52:1998;661-671.
33. Naiki H., Higuchi K., Matsushima K., Shimada A., Chen W.H., Hosokawa M. et al. Fluorimetric examination of tissue amyloid fibrils in maurine senile amyloidosis: use of the fluorescent indicator, thioflavine T. Lab. Invest. 62:1990;768-773.
34. Naiki H., Gejyo F., Nakakuki K. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry. 36:1997;6243-6250.
35. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P.et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 283:2000;1571-1577.
36. Niwa K., Kazama K., Younkin S.G., Carlson G.A., Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9:2002;61-68.
37. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687.
38. Poduslo J.F., Curran G.L., Kumar A., Frangione B., Soto C. B-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain-barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol. 39:1999;371-382.
39. Romijn H.J., Habets A.M.M.C., Mud M.T., Wolters P.S. Nerve outgrowth, synaptogenesis and bioelectric activity in fetal rat cerebral cortex tissue cultured in serum free chemically defined medium. Dev. Brain Res. 2:1982;583-589.
40. Salinero O., Moreno-Flores M.T., Caballos M.L., Wandosell F. Beta-amyloid induces cytoskeletal reorganization in cultured astrocytes. J. Neurosci. Res. 47:1997;216-223.
41. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
42. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D.et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 359:1992;325-327.
43. Shoichetman T., Skutelsky E., Lew S., Hammel I. Changes in the distribution of anionic constituents in secretory granules of mouse pancreatic acinar cells after pilocarpine-induced degranulation. J. Histochem. Cytochem. 49:2001;1199-1204.
44. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M.et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 258:1992;126-129.
45. Sinha S., Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc. Natl. Acad. Sci. U.S.A. 96:1999;11049-11053.
46. Smith-Swintosky V.-L., Gozes I., Brenneman D.E., Plata-Salaman C.R. Activity dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. Soc. Neurosci. Abstr. 26:2000;843.
47. Stege G.J.J., Renkawek K., Overkamp P.S.G., Vershuure P., Van Rijk A.F., Reijnen-Aalberts A.et al. The molecular chaperone α-B-crystallin enhances amyloid β neurotoxicity. Biochem. Biophys. Res. Commun. 262:1999;152-156.
48. Soto C., Branes M.C., Alvarez J., Inestrosa N.C. Structural determinants of the Alzheimer's amyloid beta-peptide. J. Neurochem. 63:1994;1191-1198.
49. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis, implications for Alzheimer's therapy. Nat. Med. 4:1998;827-831.
50. Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol. Med. Today. 5:1999;343-350.
51. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F.et al. Reversion of propn protein conformational changes by synthetic β-sheet breaker peptides. Lancet. 355:2000;192-197.
52. Steingart R.A., Solomon B., Brenneman D.E., Fridkin M., Gozes I. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci. 15(3):2000;137-145.
53. Vickers J.C., Dickson T.C., Adlard P.A., Saunders H.L., King C.E., McCormack G. The cause of neuronal degeneration in Alzheimer disease. Prog. Neurobiol. 60:2000;139-165.
54. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 17:1985;278-282.
55. Wisniewski T., Ghiso J., Frangione B. Alzheimer's disease and soluble Aβ Neurobiol. Aging. 15:1994;143-152.
56. Zemlyak I., Furman S., Brenneman D.E., Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regul. Pept. 96:2000;39-43.